GET THE APP

Comparison Study between Real Life and Published Data Outcome among Myelofibrosis Patients Who are Using Ruxolitinib at King Abdulaziz Medical City-Central Region | Abstract
Logo

International Journal of Medical Research & Health Sciences (IJMRHS)
ISSN: 2319-5886 Indexed in: ESCI (Thomson Reuters)

Abstract

Comparison Study between Real Life and Published Data Outcome among Myelofibrosis Patients Who are Using Ruxolitinib at King Abdulaziz Medical City-Central Region

Author(s):Yousef Al Aolah, Ahmed Alanazi, Ahmed Elmubark, Mohammed Aldhaeefi, Thamer Alanazi, Nasser Alqahtani, Mohamed Albekery, Abdulrhman alghamdi and Rami Bustami

Objectives: The aim of this study is to evaluate the efficacy and safety of Ruxolitinib among Myelofibrosis patients in real life compared to published data. Methods: In this retrospective observational chart review study we reviewed the medical records for all patients diagnosed with Myelofibrosis in King Abdulaziz Medical City who has received Ruxolitinib from March 1, 2012-December 1, 2015. The efficacy and safety results of Ruxolitinib were compared with published data. Results: A total of 20 patients were included. The average age was 63.3 (SD=11.6) years, with 55% of females. Efficacy: At week 24, only 20% of the study participant achieved spleen size reduction equal to or more than 20% with total average of 8% reduction in the spleen size as compared to 31.60% in COMFORT-1 study (p ≤ 0.001), The highest symptoms reduction observed with fatigue and bone pain (45% and 40% of the affected patients respectively) followed by Abdominal distress (35%) whereas no statistically significant difference observed in early satiety and night sweat. Weight loss showed improvement in 15% of the patients. Safety: Fatigue was observed in 45% of the patients, diarrhea (5%), dyspnea (15%), dizziness (5%), nausea (5%), constipation (10%), vomiting (5%), pain in extremities (5%), arthralgia (5%), pyrexia (5%), and abdominal pain (35%). At week 24, Platelet count decreased by 26% and hemoglobin decreased by 5% from the baseline. In general, only three reported cases for temporal or permanent drug discontinuation. Conclusion: Ruxolitinib therapy in real life as compared to published trials was associated with significant improvement in Myelofibrosis related symptoms and splenomegaly with an acceptable safety profile


Archive
Scope Categories
  • Clinical Research
  • Epidemiology
  • Oncology
  • Biomedicine
  • Dentistry
  • Medical Education
  • Physiotherapy
  • Pulmonology
  • Nephrology
  • Gynaecology
  • Dermatology
  • Dermatoepidemiology
  • Otorhinolaryngology
  • Ophthalmology
  • Sexology
  • Osteology
  • Kinesiology
  • Neuroscience
  • Haematology
  • Psychology
  • Paediatrics
  • Angiology/Vascular Medicine
  • Critical care Medicine
  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Infectious Diseases and Vaccinology
  • Hepatology
  • Geriatric Medicine
  • Bariatrics
  • Pharmacy and Nursing
  • Pharmacognosy and Phytochemistry
  • Radiobiology
  • Pharmacology
  • Toxicology
  • Clinical immunology
  • Clinical and Hospital Pharmacy
  • Cell Biology
  • Genomics and Proteomics
  • Pharmacogenomics
  • Bioinformatics and Biotechnology
  • Google scholar citation report
    Citations : 2979

    International Journal of Medical Research & Health Sciences received 2979 citations as per google scholar report

    International Journal of Medical Research & Health Sciences peer review process verified at publons

    paper.io

    agar io

    wowcappadocia.com
    cappadocia-hotels.com
    balloon-rides.net

    wormax io

    Elektronik Sigara
    Elektronik Sigara